Switch theme
Sign up to access all valuation multiples
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
2007
120
LTM Revenue $13.6M
LTM EBITDA -$2.0M
$29.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mabion has a last 12-month revenue (LTM) of $13.6M and a last 12-month EBITDA of -$2.0M.
In the most recent fiscal year, Mabion achieved revenue of $40.2M and an EBITDA of $15.4M.
Mabion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mabion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | XXX | $40.2M | XXX | XXX | XXX |
| Gross Profit | $13.3M | XXX | $30.4M | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | -$2.0M | XXX | $15.4M | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | 38% | XXX | XXX | XXX |
| EBIT | -$4.3M | XXX | $18.2M | XXX | XXX | XXX |
| EBIT Margin | -32% | XXX | 45% | XXX | XXX | XXX |
| Net Profit | -$4.1M | XXX | $10.9M | XXX | XXX | XXX |
| Net Margin | -30% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mabion's stock price is PLN 10 (or $3).
Mabion has current market cap of PLN 154M (or $40.9M), and EV of PLN 111M (or $29.4M).
See Mabion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.4M | $40.9M | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mabion has market cap of $40.9M and EV of $29.4M.
Mabion's trades at 0.7x EV/Revenue multiple, and 1.9x EV/EBITDA.
Equity research analysts estimate Mabion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mabion has a P/E ratio of -10.0x.
See valuation multiples for Mabion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40.9M | XXX | $40.9M | XXX | XXX | XXX |
| EV (current) | $29.4M | XXX | $29.4M | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | -14.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBIT | -6.8x | XXX | 1.6x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.0x | XXX | 3.7x | XXX | XXX | XXX |
| EV/FCF | 29.5x | XXX | -2.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMabion's last 12 month revenue growth is -18%
Mabion's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Mabion's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mabion's rule of X is -61% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mabion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -18% | XXX | -37% | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 69% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -61% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mabion acquired XXX companies to date.
Last acquisition by Mabion was XXXXXXXX, XXXXX XXXXX XXXXXX . Mabion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mabion founded? | Mabion was founded in 2007. |
| Where is Mabion headquartered? | Mabion is headquartered in Poland. |
| How many employees does Mabion have? | As of today, Mabion has 120 employees. |
| Is Mabion publicy listed? | Yes, Mabion is a public company listed on WAR. |
| What is the stock symbol of Mabion? | Mabion trades under MAB ticker. |
| When did Mabion go public? | Mabion went public in 2010. |
| Who are competitors of Mabion? | Similar companies to Mabion include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mabion? | Mabion's current market cap is $40.9M |
| What is the current revenue of Mabion? | Mabion's last 12 months revenue is $13.6M. |
| What is the current revenue growth of Mabion? | Mabion revenue growth (NTM/LTM) is -18%. |
| What is the current EV/Revenue multiple of Mabion? | Current revenue multiple of Mabion is 2.2x. |
| Is Mabion profitable? | Yes, Mabion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mabion? | Mabion's last 12 months EBITDA is -$2.0M. |
| What is Mabion's EBITDA margin? | Mabion's last 12 months EBITDA margin is -14%. |
| What is the current EV/EBITDA multiple of Mabion? | Current EBITDA multiple of Mabion is -14.9x. |
| What is the current FCF of Mabion? | Mabion's last 12 months FCF is $1.0M. |
| What is Mabion's FCF margin? | Mabion's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Mabion? | Current FCF multiple of Mabion is 29.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
